Affymetrix Inc. (NASDAQ: AFFX) and Luminex Corporation (NASDAQ: LMNX) today announced a distribution agreement under which eBioscience, a business unit of Affymetrix, will sell Luminex’s MAGPIX®, Luminex® 200™ and FLEXMAP 3D® multiplexed assay platforms in specified countries in the Americas, Asia and Europe. Affymetrix will sell the Luminex instruments together with ProcartaPlex® multiplexed immunoassays and QuantiGene® Plex multiplexed quantitative gene expression assays, offering complete solutions to customers working in the fields of drug discovery and development, immuno-oncology and translational research. The agreement will strengthen continued growth and adoption of Affymetrix’ bead-based assay portfolio, which serves markets growing at double-digit rates worldwide, while expanding the Luminex instrument installed base.

The distribution agreement covers the U.S., Canada, Mexico, Brazil and China as well as The Netherlands, Germany, France, U.K., Switzerland, Austria, Belgium, Ireland, Luxembourg and Poland.

“We are pleased to enter into this agreement with Luminex, the leading instrument provider supporting bead-based multiplexed assays,” said Dara Grantham Wright, senior vice president and general manager of the eBioscience business unit at Affymetrix. “This agreement deepens our relationship with Luminex, and will provide our customers an integrated solution to access a best-in-class platform with an ever-expanding, high-quality assay menu.”

“By enabling Affymetrix to offer both Luminex multiplexing instruments and Affymetrix assays, we can further drive accessibility to customers focused on disease-related research around the world,” said Todd Bennett, vice president, global sales and customer operations, Luminex Corporation. “We are very pleased to enter into this agreement, and to support Affymetrix in its efforts to bring flexible, high-quality solutions to laboratories working in the fields of drug discovery and development, immuno-oncology and translational research.”

Financial terms were not disclosed.

About xMAP-based Instruments

Luminex offers three multiplex instruments enabling laboratories to choose a platform that fits their throughput and flexibility needs. MAGPIX is the simplest, most affordable, and most compact of Luminex’s xMAP instruments. This compact multiplexing unit performs up to 50 different tests in a single reaction volume and reads a 96-well plate in just 60 minutes. The Luminex 200 System provides laboratorians the ability to perform up to 100 different tests in a single reaction volume while using either magnetic or polystyrene microspheres. FLEXMAP 3D is the platform of choice for high throughput applications. The platform is capable of simultaneously measuring up to 500 genes or proteins from a small sample. All three xMAP-based instruments run multiplexed assays for proteins or nucleic acids, whether kit-based or lab-developed.

Learn more about Luminex instruments: www.luminexcorp.com/instruments

About Luminex Corporation

Luminex is committed to applying its passion for innovation toward creating breakthrough solutions to improve health and advance science. The company is transforming global healthcare and life-science research through the development, manufacturing and marketing of proprietary instruments and assays utilizing xMAP® open-architecture multi-analyte platform, MultiCode® real-time polymerase chain reaction (PCR) and multiplex PCR-based technologies that deliver cost-effective rapid results to clinicians and researchers. Luminex's technology is commercially available worldwide and in use in leading clinical laboratories as well as major pharmaceutical, diagnostic, biotechnology and life-science companies. Luminex is meeting the needs of customers in markets as diverse as clinical diagnostics, pharmaceutical drug discovery, biomedical research including genomic and proteomic research, personalized medicine, biodefense research and food safety. For further information on Luminex Corporation and the latest advances in multiplexing using award-winning technology, please visit www.luminexcorp.com.

About Affymetrix

Affymetrix technologies enable multiplex and simultaneous analysis of biological systems at the cell, protein and gene level, facilitating the rapid translation of benchtop research into clinical and routine use for human health and wellness. Affymetrix provides leadership and support, partnering with customers in pharmaceutical, diagnostic and biotechnology companies as well as leading academic, government and nonprofit research institutes in their quest to use biology for a better world. More than 2,300 microarray systems have been shipped around the world and more than 94,000 peer-reviewed papers have been published citing Affymetrix technologies. Affymetrix is headquartered in Santa Clara, California, and has manufacturing facilities in Cleveland, San Diego, Vienna and Singapore. Affymetrix has about 1,100 employees and maintains sales and distribution operations worldwide. For more information about Affymetrix, please visit www.affymetrix.com.

Forward-looking statements

All statements in this press release that are not historical are "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix' "expectations," "beliefs," "hopes," "intentions," "strategies," or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected. These and other risk factors are discussed in Affymetrix' Form 10-K for the year ended December 31, 2014, and other SEC reports for subsequent quarterly periods.

PLEASE NOTE: Affymetrix, the Affymetrix logo, eBioscience, ProcartaPlex, and QuantiGenePlex trademarks are the property of Affymetrix, Inc. All other trademarks are the property of their respective owners.

AffymetrixMedia Contact:Mindy Lee-Olsen, 408-731-5523Vice President, Marketing Servicesmindy_lee-olsen@affymetrix.comorInvestor Contact:Doug Farrell, 408-731-5285Vice President, Investor Relationsdoug_farrell@affymetrix.comorLuminexMedia Contact:Christine Valle, 512-219-8020Sr. Manager, Global Marketingcvalle@luminexcorp.comorLuminex Investor Contact:Harriss Currie, 512-219-8020Sr. Vice President of Finance and CFOhcurrie@luminexcorp.com

Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Affymetrix Charts.
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Affymetrix Charts.